Amyloid A amyloidosis secondary to rheumatoid arthritis: An uncommon yet important complication

Current Rheumatology Reviews

Volumn 3, Issue 3, 2007, Pages 231-241

  Nakamura, Tadashi ^a  

^a Kumamoto Center for Arthritis and Rheumatology   (Japan)

Author keywords

AA amyloidosis; Genetic factor; Metabolic syndrome; Rheumatoid arthritis; SAA1.3 allele; Tailor made medicine

Indexed keywords

AMYLOID A PROTEIN; ATLIZUMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AMYLOIDOSIS; CAUSE OF DEATH; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DNA POLYMORPHISM; EARLY DIAGNOSIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; JAPANESE; KIDNEY AMYLOIDOSIS; METABOLIC SYNDROME X; MONOTHERAPY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; RACE DIFFERENCE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SURVIVAL TIME;

EID: 34548329106     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707781387581     Document Type: Review

References (126)

1. Pepys MB, Hawkins PN. In: Warrell DA, Cox TK Firth JD, Benz Jr EJ Ed, Oxford textbook of medicine. Oxford, Oxford University Press 2003; 162-73.
2. Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 2003; 35: 1608-13.
3. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001; 13: 67-73.
4. Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Bailliere's Clin Rheumatol 1999; 13: 615-28.
5. Wakhlu A, Krisnani N, Hissatia P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in Asian north Indian patients with rheumatoid arthritis. J Rheumatol 2003; 30: 948-51.
6. Baba S, Masago SA, Takahashi T. et al. A novel allelic variant of serum amyloid A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995; 4: 1083-7.
7. Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Baba S. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis: three case reports. Clin Exp Rheumatol 2003; 21: 673-4.
8. Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba. S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA antyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003; 22: 371-5.
9. Laiho K, Tiitinen S, Kaarela K, Helin H, Isomaki H. Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland. Clin Rheumatol 1999; 18: 122-3.
10. Kaipiainen-Seppauen O, Myllykangas-Luosujarvi R, Lampainen E, Ikaheimo R. Intensive treatment of rheumatoid arthritis reduces need for dialysis due to secondary amyloidosis. Scand J Rheumatol 2000; 29: 232-5.
11. Hanzenberg BPC, van Rijswijk MH. Where has secondary amyloidosis gone? Ann Rheum Dis 2000; 59: 577-9.
12. Rocken C, Shakespeare A. Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 1002; 440:114-22.
13. Rocken C, Radum D, Glasbrenner B, Malfertheiner P, Roessner A. Generalized AA-amyloidosis in a 58-year-old Caucasian woman with an 18-month history of gastrointestinal tuberculosis. Virchows Arch 1999; 434: 95-100.
14. Nakamura T, Baba S, Yamamura Y, et al. Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1γ/γ genotype in a patient with rheumatoid arthritis. Mod Rheumatol 2000; 10: 160-4.
15. Husby G, Marhaug G, Dowton B, Sletten K, Sipe JD. Serum amyloid A (SAA): biochemistry, genetics and the pathogenesis of AA amyloidosis. Amyloid 1994; 1: 119-37.
16. Malle E, Steinmetz A, Raynes JG. Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis 1993; 102: 131-46.
17. Emery P, Luqmani R. The validity of surrogate markers in rheumatic disease. Br J Rheumatol 1993; 32 (Suppl 3): 3-8.
18. Kluve-Beckerman B, Malle E, Vitt H, Pfeiffer C, Benson M, Steimetz A. Characterization of an isoclectric focusing variant of SAA1 (ASP-72) in a family of Turkish origin. Biochem Biophys Res Commun 1991; 181: 1097-102.
19. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999; 265: 501-23.
20. Kisilevsky R. Amyloidogenesis-unquestioned answers and unanswered questions. J Struct Biol 2000; 130: 99-108.
21. Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins PM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997; 4: 274-95.
22. Kindy MS, Rader DJ. Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol 1998; 152: 1387-95.
23. Hasegawa H, Nishi S, Ito S, et al. High prevalence of serum apolipoprotein E4 isoprotein in rheumatoid arthritis patients with amyloidosis. Arthritis Rheum 1996; 39: 1728-32.
24. Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute response, J Immunol 1992; 148: 480-4.
25. Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A proteinin human secondary amyloidosis: the predominant deposition of serum amyloid A1. Biochim Biophys Acta 1995; 1270: 81-6.
26. Yamada T, Wada A, Itoh Y, Itoh K. Serum amyloid A1 alleles and plasma concentrations of serum amyloid A. Amyloid 1999; 6: 199-204.
27. Yamada T, Okuda Y, Itoh Y. The frequency of serum amyloid A2 alleles in the Japanese population. Amyloid 1998; 5: 208-11.
28. Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60:124-7.
29. Xu Y, Yamada T, Satoh T, Okuda Y. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA. Clin Chem Lab Med 2006; 44: 59-63.
30. Sipe JD. Acute-phase proteins in osteoarthritis. Semin Arthritis Rheum 1995; 25: 75-86.
31. Baba S, Takahashi T, Kasama T, Shirasawa H. Identification of two novel amyloid A protein subsets coexisting in an individual patient of AA-amyloidosis. Biochim Biophys Acta 1992; 1180: 195-200.
32. Baba, S, Takahashi T, Kasama T, Fujie M, Shirasawa H. A novel polymorphism of human serum amyloid A protein, SAA1 gamma, is characterized by alanines at both residues 52 and 57. Arch Biochem. Biophys 1993; 303: 361-6.
33. Moriguchi M, Terai C, Koseki Y, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999; 105: 360-6.
34. Booth DR, Booth SE, Gillmore JD, Hawkins PN, Pepys MB. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998; 5: 262-5.
35. Yamada T, Okuda Y, Takasugi K, et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 2003; 10: 7-11.
36. Moriguchi M, Kaneko H, Terai C, et al. Relative transcriptional activities of SAA1 promoters polymorphic at position -13T(T/C): potential association between increased transcription and amyloidosis. Amyloid 2005; 12: 26-32.
37. Moriguchi M, Terai C, Koseki Y, et al. Genotypes at SAA1 locus correlate with the clinical severity of AA-amyloidosis. Amyloid 2001; 8:115-20.
38. Ajiro J, Narita I, Sato S, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis on Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16: 294-9.
39. Meyer JM, Evans TI, Small RE, et al. HLA-DRB1 genotype influences risk for and severity of rheumatoid arthritis. J Rheumatol 1999; 26: 1024-34.
40. Gonzalez-Gay MA, Garcia-Porrua C. Hajeer AH. Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31: 355-60.
41. Fries JF, Wolfe F, Apple R, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002; 46: 2320-9.
42. Turesson C, Weyand CM, Matteson EL. Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations? Arthritis Rheum 2004; 51: 853-63.
43. Wakitani S, Imoto K, Murata N, Oonishi H, Ochi T, Yoneda M. An association between the natural course of shoulder joint destruction in rheumatoid arthritis and HLA-DRB1 *0405 in Japanese patients. Scand J Rheumatol 1998; 27: 146-8.
44. Kim HY, Kim TG, Park SH, Lee SH, Cho CS, Han H. Predominance of HLA-DRB1 *0405 in Korean patients with rheumatoid arthritis. Ann Rheum Dis 1995; 54: 988-90.
45. MacGregor A, Ollier W, Thomson W, Jawaheer D, Silman A. HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity. J Rheumatol 1995; 22: 1032-6.
46. Weyand CM, McCarthy TG, Goronzy JJ. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995; 95: 2120-6.
47. Migita K, Nakamura T, Maeda Y, et al. HLA-DRB1 *04 alleles in Japanese rheumatoid arthritis patients with AA amyloidosis. J Rheumatol 2006; 33: 2120-3.
48. Moriguchi M, Terai C, Kaneko H, et al. A novel single-nucleotide polymorphism at 5′-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum 2001; 44: 1266-72.
49. 1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis. Inflammation 1993; 17: 33-45.
50. Migita. K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75: 371-5.
51. Upragarin N, Landman WJM, Gaastra W, Gruys E. Extrahepatic production of acute phase serum amyloid A. Histol Histopathol 2005; 20: 1295-307.
52. Migita K, Abiru S, Nakamura M, et al. Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Lett 2004; 569: 235-9.
53. Gomez-Casanovas E, Sanmarti R, Sole M, Canate JD, Munoz-Gomez J. The clinical significance of amyloid fat deposit in rheumatoid arthritis. A systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001; 44: 66-72.
54. Suzuki A, Ohosone Y, Obana M, et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994; 21: 33-6.
55. Joss N. McLaughlin K, Simpson K, Boulton-Jones JM. Presentation, survival and prognostic markers in AA amyloidosis Q J Med 2000; 93: 535-42.
56. Ishii W, Matsuda M, Nakamura A, Nakamura N, Suzuki A, Ikeda S. Abdominal fat aspiration biopsy and genotyping of serum amyloid A contribute to early diagnosis of reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003; 42: 800-5.
57. Gratacos J, Orellana, C, Sanmarti R, et al. Secondary amyloidosis in ankylosing spondylitis: a systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997; 24: 912-5.
58. Mansoury TME, Hazenberg BPC, Badawy SAE, et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002; 61: 42-7.
59. Kobayashi H, Tada S, Fuchigami T, et al. Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996;. 35: 44-9.
60. Carmona L, Gonzalez-Alvaro L, Balsa A, Belmonte MA, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003; 62: 897-900.
61. Gonzalez-Alvaro I, Carmona L, Balsa A, et al. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Reumatol 2003; 36: 697-764.
62. Misra R, Wakhlu A, Krishnani N, Hissaaria P, Aggarwal A. Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol 2004; 31: l031-4.
63. Nakamura T, Tomoda K, Tsukano M, Yamamura Y, Baba S. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to-rheumatoid arthritis. Mod Rheumatol 2004; 14: 498-501.
64. Faulkes DJ, Betts X, Woo, P. Characterization of five human serum amyloid A1 alleles. Amyloid 1994; 1: 255-62.
65. Gillmore JO, Levitt LB, Jersey MA, PepysMB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-9.
66. Maini RN, Breedvelt FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-65.
67. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003; 21 (Suppl 31): 154-64.
68. Ishii W, Matsuda M, Nakamura N, et al. Phenol Congo red staining enhances the diagnostic value of abdominal fat aspiration biopsy in reactive AA amyloidosis secondary to rheumatoid arthritis. Intern Med 2003; 42: 400-5.
69. Uda H, Yokota A, Kobayashi K, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol 2006; 33: 1482-7.
70. Tuglular S, Yalcinkaya F, Paydas S, et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002; 17: 2003-5.
71. Kuroda T, Tanebe N, Sato H, et al. Outcome of patients with reactive amyloidosis associated with rheumatoid arthritis in dialysis treatment. Rheumatol Int 2006; 26: 1147-53.
72. Okuda Y, Takasugi K, Oyama T, Oyama H, Nanba S, Miyamoto T. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. Ann Rheum Dis 1997; 56: 535-41
73. Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 2003; 21: 343-6.
74. Kuroda T, Tanabe N, Harada T, et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2006; 25: 498-505.
75. Nakamura T, Higashi S, Tomoda K, Tsukano M, Baba S, Shono M. Significance of SAA1.3 allele genotypte in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology 2006; 45: 43-9.
76. Baba S, Nakai H, Nakamura T, Miyamoto S, Ohta Y, Tsutsui Y. Npvel polymorphism in the 5′-flanking region of the human serum amyloid A1(SAA1) gone and an association with reactive AA-amyloidosis. Amyloid 2001; 8 (Suppl 2): 41-3.
77. Odabas AR, Cetinkaya R, Selcuk Y, Erman Z, Bilen H. Clinical and biochemical outcome of renal amyloidosis. Int J Clin Pract 2002; 56: 342-4.
78. Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 1991; 70: 246-56.
79. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994; 37: 481-94.
80. Voskuyl AE, Zwinderman AH, Weestedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996; 39: 266-71.
81. McGill NW, Tuck R, Hassall JE. Severe autonomic neuropathy in amyloidosis secondary to rheumatoid arthritis. Aust N Z J Med 1986; 16: 705-7.
82. Arima T, Ando Y, Ando E, et al. Secondary amyloidosis with severe autonomic dysifunctions. J Auton Nerv Sys 1995; 52: 77-81.
83. Edomonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J 1979; 2: 173-5.
84. Mpofu S, Teh LS, Smith PJ, Moots RJ, Hawkins PN. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. Rheumatology 2003; 42: 362-6.
85. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 957-65.
86. Lindqvist E, Jonsson K, Saxne T, Bkerhardt K, Curse of radiographic damage over 10 years in a cohort with early rheumatopid arthritis. Ann Rheum Dis 2003; 62: 611-6.
87. Hazenberg BPC, van Rijswijk MH. Clinical and therapeutic aspects of AA amyloidosis. Bailliere's Clin Rheumatol 1994; 8: 661-90.
88. Grateau G, Jero I, Rouaghe S, et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets-Inflammation & Allergy 2005; 4: 57-65.
89. Dhillon V, Woo P, Isenburg D. Amyloidosis in the rheumatic diseases. Ann Rheum Dis 1989; 48: 696-701.
90. Hushy G. Amyloidosis in rheumatoid arthritis. Ann Clin Res 1975; 7: 154-67.
91. Tiitinen S, Kaarela K, Helin H, et al. Amyloidosis-incidence and early risk factors in patients with rheumatoid arthritis. Scand J Rheumatol 1993; 22: 158-61.
92. David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Antyloidosis in juvenile chronic arthritis: a morbidity and mortality study. Clin Exp Rheumatol 1993; 2: 85-90.
93. Keysser G, Keysser C, Keysser M. Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term followup of 108 patients. Z Rheumatol 1998; 57: 101-7.
94. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatoid arthritis. Ann Rheum Dis 1987; 46: 757-62.
95. Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987; 6: 27-38.
96. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993; 20: 2051-7.
97. Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology 2001; 40: 821-5.
98. Shapiro DL, Spiera H. Regression of the nephrotic syndrome in rheumatoid arthritis and amyloidosis treated with azathioprine. A case report. Arthritis Rheum 1995; 38: 1851-4.
99. Castell JV, Gomez-Lechon MJ, David M, et al. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 1988; 232: 347-50.
100. Smith JW, McDonald TL. Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol 1992; 90: 293-9.
101. Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun 2004; 314: 363-9.
102. Migita K, Yamasaki K, Shibatomi H, et al. Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes. Clin Exp Immumol 2001; 123: 408-11.
103. Maezawa A, Hironuma K, Mitsuhashi H, el al. Combined treatment with cyclophosphamide and predidsolone can induce remission of nephrotic syndrome in apatient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 1994; 42: 30-2.
104. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26: 267-85.
105. Matsuda M, Morita H, Ikeda S. Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid. Intern Med 2002; 41: 403-7.
106. Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to sysytemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 2005; 12: 48-53.
107. Lipsky PE, van der Heijde DMFM, Clair EWS, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
108. Klareskog L, van der Heiji DMFM, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675-81.
109. Smith GR, Tymmus KE, Falk M. Etanercept treatrment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J 2004; 34: 570-2.
110. Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002; 46: 2571-3.
111. Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, Olive A. Anti-TNF treatment in secondary amyloidosis. Rheumatology 2003; 42: 1425-6.
112. Gottenberg J-E, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. Arthritis Rheum 2003; 48: 2019-24.
113. Ravindran J, Shenker N, Bhalla AK, Lachmann H, Hawkins P. Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-α blockade. Rheumatology 2004; 43: 669-72.
114. Fernandes-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005; 118: 552-6.
115. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizmab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006; 54: 2997-3000.
116. Nakamura T, Higashi S. Tomoda Y, Tsukano K Baba S. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Exp Rheumatol 2007 (Accepted).
117. Kawai S, Kaburaki J. Increased serum lipoprotein(a) levels in systemic lupus erythematosus with myocardial and cerebral infarctions. J Rheumatol 1995; 22: 1210-1.
118. Asanuma Y, Kawai S, Aoshima H, et al. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 443-7.
119. Meek RL, Urieli SS, Beneditt EP. Expression on apolipoprotein serum amyloid A mRNA in human atherosclerotic lesion and cultured vascular cells. Implication for serum amyloid A function. Proc Nad Acad Sci (USA) 1994; 91: 1386-90.
120. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179-82.
121. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
122. 2 and lactoferrin release in adherent human polymorphonuclear leukocytes. J Leukocyte Biol 1994; 56: 105-9.
123. Nakamura T, Abe A, Balazovich KJ, et al. Ceramide regulates oxidant release in adherent human neutrophils. J Biol Chem 1994; 269: 18384-9.
124. Whicher J. Biasucci L, Rifai N. Inflammation, the acute phase response and atherosclerosis. Clin Chem Lab Med 1999; 37: 495-503.
125. Pitsavos C, Panagiotakos DB, Chrysohoou C, Kavouras S, Stefanadis C. The associations between physical activity, inflammation, and coagulation markers, in people with metabolic syndrome: the ATTICA study. Eur J Cardiovascut Prevent Rehabili 2005; 12: 151-8.
126. Ueda M, Ando Y, Nakamura M, et al. FK506 inhibits murine AA amyloidosis. Possible involvement of T cells in amyloidogenesis. J Rheumatol 2006; 33: 2260-70.